索拉非尼治疗肝细胞癌的疗效评价及不良反应

摘要

目的:观察索拉非尼治疗肝细胞癌的临床疗效及不良反应.方法:回顾性分析我院2008年7月至2009年12月间应用索拉非尼400mg每日两次治疗21例肝细胞癌患者的临床疗效与不良反应.结果:2例由于在服药后1月内出现肝功能异常而停药,未进行肿瘤评价.19例接受过1次以上实体瘤治疗反应评价标准(RECIST Response Evaluation Criteria in Solid Tumours 1.0版)的评价,其中无客观缓解者,14例(73.7%)疾病稳定且稳定时间大于3月.5例(26.3%)持续肿瘤进展.药物不良反应最常见的为手足皮肤反应、高血压、腹泻,其次有脱发、乏力、纳差、口腔溃疡、肝功能异常、发热等,不良反应一般在服药后1-2周内出现,其中有2例不能耐受不良反应而减少药物剂量,2例由于肝功能异常而停药.结论:索拉非尼治疗肝细胞癌患者以疾病稳定者多见,应严密监测并及时处理不良反应,以保证持续用药.%Objective :To investigate and discuss the therapeutic evaluation and adverse effects of sorafenib in the treatment of hepatocellular carcinoma. Methods: The clinical data of 21 hepatocellular carcinoma( HCC ) patients treated with sorafenib were analyzed retrospectively. Results: According to Response Evaluation Criteria in Solid Tumours ( RECIST 1.0 )criteria, 14 cases( 73.7％ )achieved stable disease ( SD ) , no complete response and partial response, 5( 26.3％ ) cases progressive disease. The common adverse effects included hand -foot skin reaction ( HFSR ), hypertension, diarrhea. The adverse reaction usually occurred 1 - 2 weeks after drug administration. Conclusion: In the treatment effect of sorafenib, SD is common. We should monitor the adverse effects of sorafenib and give management in order to ensure drug administration.